195 related articles for article (PubMed ID: 12505056)
1. Molecular mechanisms of myocardial remodeling. The role of aldosterone.
Delcayre C; Swynghedauw B
J Mol Cell Cardiol; 2002 Dec; 34(12):1577-84. PubMed ID: 12505056
[TBL] [Abstract][Full Text] [Related]
2. Cardiac aldosterone production and ventricular remodeling.
Delcayre C; Silvestre JS; Garnier A; Oubenaissa A; Cailmail S; Tatara E; Swynghedauw B; Robert V
Kidney Int; 2000 Apr; 57(4):1346-51. PubMed ID: 10760065
[TBL] [Abstract][Full Text] [Related]
3. Aldosterone and myocardial fibrosis in heart failure.
Brilla CG
Herz; 2000 May; 25(3):299-306. PubMed ID: 10904856
[TBL] [Abstract][Full Text] [Related]
4. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis.
Silvestre JS; Heymes C; Oubénaïssa A; Robert V; Aupetit-Faisant B; Carayon A; Swynghedauw B; Delcayre C
Circulation; 1999 May; 99(20):2694-701. PubMed ID: 10338465
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist.
Bos R; Mougenot N; Findji L; Médiani O; Vanhoutte PM; Lechat P
J Cardiovasc Pharmacol; 2005 Jan; 45(1):8-13. PubMed ID: 15613973
[TBL] [Abstract][Full Text] [Related]
6. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
Dieterich HA; Wendt C; Saborowski F
Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
[TBL] [Abstract][Full Text] [Related]
7. Induction of cardiac fibrosis by aldosterone.
Lijnen P; Petrov V
J Mol Cell Cardiol; 2000 Jun; 32(6):865-79. PubMed ID: 10888242
[TBL] [Abstract][Full Text] [Related]
8. Mineralocorticoid receptor antagonism and cardiac remodeling in ischemic heart failure.
Fraccarollo D; Galuppo P; Bauersachs J
Curr Med Chem Cardiovasc Hematol Agents; 2004 Oct; 2(4):287-94. PubMed ID: 15320779
[TBL] [Abstract][Full Text] [Related]
9. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion.
Sun Y; Ramires FJ; Weber KT
Cardiovasc Res; 1997 Jul; 35(1):138-47. PubMed ID: 9302358
[TBL] [Abstract][Full Text] [Related]
10. Aldosterone inhibition and cardiovascular protection: more important than it once appeared.
Martinez FA
Cardiovasc Drugs Ther; 2010 Aug; 24(4):345-50. PubMed ID: 20676926
[TBL] [Abstract][Full Text] [Related]
11. Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction.
Katada J; Meguro T; Saito H; Ohashi A; Anzai T; Ogawa S; Yoshikawa T
Circulation; 2005 May; 111(17):2157-64. PubMed ID: 15851599
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis.
Robert V; Heymes C; Silvestre JS; Sabri A; Swynghedauw B; Delcayre C
Hypertension; 1999 Apr; 33(4):981-6. PubMed ID: 10205234
[TBL] [Abstract][Full Text] [Related]
13. [Hypertension-induced fibrosis: a balance story].
Azibani F; Fazal L; Chatziantoniou C; Samuel JL; Delcayre C
Ann Cardiol Angeiol (Paris); 2012 Jun; 61(3):150-5. PubMed ID: 22681982
[TBL] [Abstract][Full Text] [Related]
14. Blocking aldosterone in heart failure.
Shafiq MM; Miller AB
Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):379-85. PubMed ID: 19661156
[TBL] [Abstract][Full Text] [Related]
15. Mineralocorticoids and cardiovascular diseases. Status of knowledge from experimental and clinical studies.
Pasquale PD; Stefano GD; Paterna S
Ital Heart J; 2000 Sep; 1(9):595-604. PubMed ID: 11130838
[TBL] [Abstract][Full Text] [Related]
16. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension.
Brilla CG; Matsubara LS; Weber KT
Am J Cardiol; 1993 Jan; 71(3):12A-16A. PubMed ID: 8421998
[TBL] [Abstract][Full Text] [Related]
17. Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure.
Zannad F; Radauceanu A
Heart Fail Rev; 2005 Jan; 10(1):71-8. PubMed ID: 15947894
[TBL] [Abstract][Full Text] [Related]
18. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
Brilla CG; Schencking M; Scheer C; Rupp H
Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
[TBL] [Abstract][Full Text] [Related]
19. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction.
Hayashi M; Tsutamoto T; Wada A; Maeda K; Mabuchi N; Tsutsui T; Matsui T; Fujii M; Matsumoto T; Yamamoto T; Horie H; Ohnishi M; Kinoshita M
J Am Coll Cardiol; 2001 Nov; 38(5):1375-82. PubMed ID: 11691511
[TBL] [Abstract][Full Text] [Related]
20. Aldosterone-synthase overexpression in heart: a tool to explore aldosterone's effects.
Heymes C; Garnier A; Fuchs S; Bendall JK; Nehme J; Ambroisine ML; Robidel E; Swynghedauw B; Milliez P; Delcayre C
Mol Cell Endocrinol; 2004 Mar; 217(1-2):213-9. PubMed ID: 15134820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
